HOLX Stock Overview
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Hologic, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$72.00 |
| 52 Week High | US$78.30 |
| 52 Week Low | US$60.90 |
| Beta | 1.02 |
| 1 Month Change | 0.39% |
| 3 Month Change | 4.20% |
| 1 Year Change | -5.04% |
| 3 Year Change | 30.43% |
| 5 Year Change | 74.33% |
| Change since IPO | 87.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| HOLX | AT Medical Equipment | AT Market | |
|---|---|---|---|
| 7D | 1.4% | 0.3% | -0.08% |
| 1Y | -5.0% | 0.9% | 2.6% |
Return vs Industry: HOLX underperformed the Austrian Medical Equipment industry which returned 0.9% over the past year.
Return vs Market: HOLX underperformed the Austrian Market which returned 2.6% over the past year.
Price Volatility
| HOLX volatility | |
|---|---|
| HOLX Average Weekly Movement | 2.2% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in AT Market | 5.2% |
| 10% least volatile stocks in AT Market | 1.7% |
Stable Share Price: HOLX has not had significant price volatility in the past 3 months.
Volatility Over Time: HOLX's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 6,990 | Steve MacMillan | www.hologic.com |
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Hologic, Inc. Fundamentals Summary
| HOLX fundamental statistics | |
|---|---|
| Market cap | €16.63b |
| Earnings (TTM) | €480.43m |
| Revenue (TTM) | €3.70b |
34.9x
P/E Ratio4.5x
P/S RatioIs HOLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HOLX income statement (TTM) | |
|---|---|
| Revenue | US$3.97b |
| Cost of Revenue | US$1.55b |
| Gross Profit | US$2.42b |
| Other Expenses | US$1.91b |
| Earnings | US$515.10m |
Last Reported Earnings
Dec 30, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 2.19 |
| Gross Margin | 60.99% |
| Net Profit Margin | 12.98% |
| Debt/Equity Ratio | 55.0% |
How did HOLX perform over the long term?
See historical performance and comparison